Vyepti is an FDA- and MHRA-recognised CGRP monoclonal antibody infusion administered intravenously for the preventive treatment of migraine in adults. Unlike daily oral preventatives, Vyepti is given as a single infusion every three months, making it a practical option for patients who struggle with tablet adherence or have not responded to conventional migraine treatment.

As a migraine specialist clinic, we offer this infusion therapy as part of a comprehensive neurology-led prevention strategy. Vyepti works by targeting calcitonin gene-related peptide (CGRP), a key molecule involved in migraine attacks, reducing both the frequency and severity of episodes.

Suitable for: Adults with episodic or chronic migraine who have not achieved adequate control with other preventive treatments.